Letters sent to healthcare professionals in July 2015

Last month, letters were sent regarding SGLT2 inhibitors and Xgeva▼ (denosumab).

• From: Medicines and Healthcare products Regulatory Agency
• Published: 19 August 2015

Last month, letters were sent regarding:

• .SGLT2 inhibitors: risk of diabetic ketoacidosis (see also June Drug Safety Update)

• Xgeva▼ (denosumab): contraindication in patients with unhealed lesions from dental or oral surgery; introduction of patient reminder card for risk of osteonecrosis of the jaw (see also July Drug Safety Update

Article citation: Drug Safety Update volume 9 issue 1 August 2015: 2

Published 19 August 2015